Skip to main content
Top
Published in: Acta Diabetologica 1/2010

01-03-2010 | Editorial

Diabetic kidney disease: act now or pay later

Authors: Robert C. Atkins, Paul Zimmet

Published in: Acta Diabetologica | Issue 1/2010

Login to get access

Excerpt

In 2003, the International Society of Nephrology and the International Diabetes Federation launched a booklet called “Diabetes in the Kidney: Time to Act” [1] to highlight the global pandemic of type 2 diabetes and diabetic kidney disease. It aimed to alert governments, health organizations, providers, doctors and patients to the increasing health and socio-economic problems due to diabetic kidney disease and its sequelae, end-stage kidney disease requiring dialysis and cardiovascular death. Seven years later, the same message has become even more urgent. World Kidney Day 2010, under the auspices of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), together with the International Diabetes Federation (IDF), provides yet another chance to underline the importance of diabetic kidney disease, stress the lack of awareness of this illness at both public and government levels and emphasize that its management involves prevention, recognition and treatment of its complications. Primary prevention of type 2 diabetes will require massive lifestyle changes in the developing and developed world supported by strong governmental commitment to promote lifestyle and societal change. …
Literature
1.
go back to reference International Diabetes Federation and International Society of Nephrology, Diabetes and kidney disease: time to act. 2003: Brussels International Diabetes Federation and International Society of Nephrology, Diabetes and kidney disease: time to act. 2003: Brussels
2.
go back to reference Zimmet P, Alberti K, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMed Zimmet P, Alberti K, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMed
3.
go back to reference King H, Aubert R, Herman W (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431CrossRefPubMed King H, Aubert R, Herman W (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431CrossRefPubMed
5.
go back to reference Sicree R, Shaw J, Zimmet P (2006) Diabetes and impaired glucose tolerance. In: Gan D (ed) Diabetes atlas, 3rd edn. International Diabetes Federation, Brussels, pp 15–109 Sicree R, Shaw J, Zimmet P (2006) Diabetes and impaired glucose tolerance. In: Gan D (ed) Diabetes atlas, 3rd edn. International Diabetes Federation, Brussels, pp 15–109
6.
go back to reference Reutens AT, Prentice L, Atkins R (2008) The epidemiology of diabetic kidney disease. In: Ekoé J et al (eds) The epidemiology of diabetes mellitus, 2nd edn. Wiley, Chichester, pp 499–518 Reutens AT, Prentice L, Atkins R (2008) The epidemiology of diabetic kidney disease. In: Ekoé J et al (eds) The epidemiology of diabetes mellitus, 2nd edn. Wiley, Chichester, pp 499–518
7.
go back to reference National Institutes of Health, National Institute of Diabetes, Digestive, Kidney Diseases (2007) International comparisons, in annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, pp 239–254 National Institutes of Health, National Institute of Diabetes, Digestive, Kidney Diseases (2007) International comparisons, in annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, pp 239–254
8.
go back to reference McDonald S, Excell L, Livingston B (eds) (2008) Appendix II, in ANZDATA Registry Report 2008. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, pp 1–97 McDonald S, Excell L, Livingston B (eds) (2008) Appendix II, in ANZDATA Registry Report 2008. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, pp 1–97
9.
go back to reference Yamagata K et al (2008) Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12:1–8CrossRefPubMed Yamagata K et al (2008) Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12:1–8CrossRefPubMed
10.
go back to reference Lysaght M (2002) Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 13:S37–S40PubMed Lysaght M (2002) Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 13:S37–S40PubMed
11.
go back to reference Adler A et al (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed Adler A et al (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed
12.
go back to reference Retnakaran R et al (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes 55(6):1832–1839CrossRefPubMed Retnakaran R et al (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes 55(6):1832–1839CrossRefPubMed
13.
go back to reference Parving H et al (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69(11):2057–2063CrossRefPubMed Parving H et al (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69(11):2057–2063CrossRefPubMed
14.
go back to reference Ninomiya T et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20(8):1813–1821CrossRefPubMed Ninomiya T et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20(8):1813–1821CrossRefPubMed
15.
go back to reference Dunstan D et al (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 25(5):829–834CrossRefPubMed Dunstan D et al (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 25(5):829–834CrossRefPubMed
16.
go back to reference White S et al (2008) Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 188(4):204–208PubMed White S et al (2008) Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 188(4):204–208PubMed
17.
go back to reference Whaley-Connell A et al (2009) Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53(Suppl 4):S11–S21CrossRefPubMed Whaley-Connell A et al (2009) Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53(Suppl 4):S11–S21CrossRefPubMed
18.
go back to reference Thomas M, Viberti G, Groop P (2008) Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 4(1):2–3CrossRefPubMed Thomas M, Viberti G, Groop P (2008) Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 4(1):2–3CrossRefPubMed
19.
go back to reference Holman R et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589CrossRefPubMed Holman R et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589CrossRefPubMed
20.
go back to reference Bilous R (2008) Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 25(Suppl 2):25–29CrossRefPubMed Bilous R (2008) Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 25(Suppl 2):25–29CrossRefPubMed
21.
go back to reference Gaede P et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580–591CrossRefPubMed Gaede P et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580–591CrossRefPubMed
22.
go back to reference Patel A et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed Patel A et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed
23.
go back to reference Group AC et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef Group AC et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
24.
go back to reference Zoungas S et al. (2009) The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care Aug 3 [Epub ahead of print] Zoungas S et al. (2009) The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care Aug 3 [Epub ahead of print]
25.
go back to reference Ruggenenti P et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351(19):1941–1951CrossRefPubMed Ruggenenti P et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351(19):1941–1951CrossRefPubMed
26.
go back to reference Parving H et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345(12):870–878CrossRefPubMed Parving H et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345(12):870–878CrossRefPubMed
27.
go back to reference Lewis E et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345:851–860CrossRef Lewis E et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345:851–860CrossRef
28.
go back to reference Burney B, Kalaitzidis R, Bakris G (2009) Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 18(2):107–111CrossRefPubMed Burney B, Kalaitzidis R, Bakris G (2009) Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 18(2):107–111CrossRefPubMed
Metadata
Title
Diabetic kidney disease: act now or pay later
Authors
Robert C. Atkins
Paul Zimmet
Publication date
01-03-2010
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2010
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-010-0175-7

Other articles of this Issue 1/2010

Acta Diabetologica 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.